Summary: UnitedHealthcare modified its Medicare Advantage outpatient drug and Part B medications coverage policy, effective April 2, 2026. Here's what billing teams need to know before that date.
UnitedHealthcare updated its Medicare Advantage Medical Policy covering outpatient and Part B medications and drugs. This coverage policy governs how UnitedHealthcare processes claims for physician-administered drugs billed under Medicare Advantage plans. The policy does not list specific CPT or HCPCS codes in the available data — but if your team handles outpatient drug billing for UnitedHealthcare Medicare Advantage members, this change is on your radar now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | UnitedHealthcare (Medicare Advantage) |
| Policy | Medications/Drugs (Outpatient/Part B) – Medicare Advantage Medical Policy |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | April 2, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, rheumatology, neurology, infusion therapy, primary care, any specialty billing physician-administered drugs under Medicare Advantage |
| Key Action | Audit your Medicare Advantage outpatient drug claims against the updated coverage criteria before April 2, 2026 |
UnitedHealthcare Part B Drug Coverage Criteria and Medical Necessity Requirements 2026
The UnitedHealthcare outpatient drug coverage policy for Medicare Advantage sits at the intersection of two billing worlds: Medicare Part B drug rules and UnitedHealthcare's own plan-level requirements. That combination creates real exposure. Plans have flexibility under Medicare Advantage to tighten — or sometimes expand — coverage criteria beyond traditional Medicare. This policy update is a signal to review where your claims stand.
For Part B drugs billed under Medicare Advantage, medical necessity is the central battleground. Traditional Medicare covers Part B drugs when a drug is reasonable and necessary for the diagnosis or treatment of the patient's condition. UnitedHealthcare's Medicare Advantage policy can layer additional criteria on top of that baseline — diagnosis-specific requirements, step therapy, or dosing limits that Medicare fee-for-service wouldn't impose.
The available policy data does not include specific coverage criteria text from the updated document. What the record confirms is that this is a modification — meaning something in the prior version changed. Before April 2, 2026, you need to pull the updated policy directly from UnitedHealthcare's provider portal and compare it line by line against what your billing team has been following.
Prior authorization is standard for most high-cost Part B drugs under UnitedHealthcare Medicare Advantage. If this modification changes which drugs require prior auth, which diagnosis codes satisfy medical necessity, or which step therapy requirements apply, your team needs to know before the first claim goes out post-April 2.
UnitedHealthcare Part B Drug Exclusions and Non-Covered Indications
Medicare Advantage plans can restrict coverage for drugs that traditional Medicare covers, and they can apply non-coverage designations for off-label use, experimental indications, or situations where step therapy hasn't been satisfied. UnitedHealthcare's outpatient drug coverage policy historically draws those lines.
The available policy data does not include specific exclusion language from this modified version. That gap matters. If the modification added new non-covered indications or tightened the definition of what qualifies as medically necessary for a particular drug category, you won't find it here — you'll find it in the full policy on UnitedHealthcare's provider portal.
Don't wait for a claim denial to discover what changed. Pull the policy now.
Coverage Indications at a Glance
The available policy data does not include indication-level coverage details for this modified policy. The table below reflects what the record confirms:
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Outpatient/Part B physician-administered drugs, Medicare Advantage | Modified — specific criteria not available in current data | Not listed in available data | Review updated UHC policy document directly before April 2, 2026 |
| Prior authorization requirements for Part B drugs | Likely present — confirm in updated policy | Not listed in available data | PA requirements may have changed with this modification |
| Step therapy or fail-first requirements | Possible — confirm in updated policy | Not listed in available data | Common in UHC Medicare Advantage drug policies |
UnitedHealthcare Part B Drug Billing Guidelines and Action Items 2026
This is where your energy goes between now and April 2, 2026. Part B drug billing under Medicare Advantage is already complex. A policy modification without clear public detail means you need to close the information gap yourself. Here's how:
| # | Action Item |
|---|---|
| 1 | Pull the updated policy before April 2, 2026. Go to UnitedHealthcare's provider portal and download the current version of the Medications/Drugs (Outpatient/Part B) Medicare Advantage Medical Policy. Don't rely on a cached or printed version your team has been using. Confirm the version date matches the April 2, 2026 effective date. |
| 2 | Do a line-by-line comparison against the prior version. The change type is "Modified," not "New." That means something specific shifted. Compare coverage criteria, medical necessity language, prior authorization requirements, and any drug-specific or diagnosis-specific rules. If you don't have the prior version, request it from your UnitedHealthcare provider rep. |
| 3 | Check your prior auth workflows for Part B drugs. If the modification changed which drugs require prior authorization — or what clinical documentation supports medical necessity — your pre-authorization team needs updated workflows before April 2. A PA approved under old criteria may not satisfy the new standard. |
| 4 | Review your charge capture process for physician-administered drugs. Outpatient drug billing under Medicare Advantage typically uses HCPCS J-codes for the drug plus an administration code. If the coverage policy modified which diagnoses or clinical scenarios justify a specific drug, your charge capture needs to reflect that. Coding a drug to a diagnosis that no longer satisfies the updated medical necessity criteria is a direct path to claim denial. |
| 5 | Flag any claims in the pipeline for dates of service on or after April 2, 2026. Any claim for a Part B drug under a UnitedHealthcare Medicare Advantage plan with a DOS on or after April 2 falls under the new policy. If those claims are already being prepared based on old criteria, stop and review them. |
| 6 | Talk to your compliance officer. Part B drug billing under Medicare Advantage involves federal anti-kickback and false claims exposure. If you're uncertain how the updated policy applies to your patient mix or drug portfolio, don't guess. Loop in your compliance officer before the effective date. This is especially true for high-cost drugs in oncology, rheumatology, or infusion therapy where a single claim can represent significant reimbursement. |
| 7 | Set up policy monitoring. This modification came through on April 2, 2026, but UnitedHealthcare Medicare Advantage policies update regularly. If your billing team isn't tracking UHC policy changes in real time, you're finding out about changes through denials — which is the most expensive way to learn. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Part B Drugs Under UnitedHealthcare Medicare Advantage
Codes Listed in This Policy
The UnitedHealthcare Medications/Drugs (Outpatient/Part B) Medicare Advantage Medical Policy does not list specific CPT, HCPCS, or ICD-10 codes in the available policy data.
This does not mean the policy is code-agnostic. Part B outpatient drug billing relies heavily on HCPCS J-codes (for specific drugs), Q-codes (for certain biosimilars and other agents), and CPT administration codes. The policy almost certainly references these in the full document. The available data simply doesn't surface them.
What Your Team Should Do
Pull the full policy and identify every code category it addresses. HCPCS J-code coverage can be diagnosis-dependent under Medicare Advantage. If the policy modification changed the diagnosis criteria for any drug category, the J-codes tied to those drugs are directly affected.
Do not treat this as low-stakes because the available data lacks specifics. Part B drug reimbursement under Medicare Advantage is high-dollar, and billing guidelines for this category change regularly. The absence of code data here is a limitation of the available summary — not a signal that the policy is simple.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.